Recent advances in T-cell immunotherapy for haematological malignancies

British Journal of Haematology

Volumn 176, Issue 5, 2017, Pages 688-704

  Rouce, Rayne H ^a,b   Sharma, Sandhya ^a   Huynh, Mai ^a   Heslop, Helen E ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

immunotherapy; lymphoma; T cells

Indexed keywords

BENDAMUSTINE; BUSULFAN; CARMUSTINE; CD19 ANTIGEN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; MELPHALAN; PENTOSTATIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; VIRUS ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; GENE EDITING; GENE TRANSFER; HEMATOLOGIC MALIGNANCY; HUMAN; NONHODGKIN LYMPHOMA; NONHUMAN; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUMOR ESCAPE; ADOPTIVE IMMUNOTHERAPY; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; TRANSPLANTATION; TRENDS;

ANTIGENS, CD19; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES;

EID: 85006138028     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14470     Document Type: Review

References (101)

1. Ali, S.A., Shi, V., Maric, I., Wang, M., Stroncek, D.F., Rose, J.J., Brudno, J.N., Stetler-Stevenson, M., Feldman, S.A., Hansen, B.G., Fellowes, V.S., Hakim, F.T., Gress, R.E. & Kochenderfer, J.N. (2016) T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood, 128, 1688–1700.
2. Alyea, E.P., Soiffer, R.J., Canning, C., Neuberg, D., Schlossman, R., Pickett, C., Collins, H., Wang, Y., Anderson, K.C. & Ritz, J. (1998) Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood, 91, 3671–3680.
3. Arber, C., Feng, X., Abhyankar, H., Romero, E., Wu, M.F., Heslop, H.E., Barth, P., Dotti, G. & Savoldo, B. (2015) Survivin-specific T cell receptor targets tumor but not T cells. The Journal of Clinical Investigation, 125, 157–168.
4. Armand, P. (2015) Immune checkpoint blockade in hematologic malignancies. Blood, 125, 3393–3400.
5. Bachireddy, P., Burkhardt, U.E., Rajasagi, M. & Wu, C.J. (2015) Haematological malignancies: at the forefront of immunotherapeutic innovation. Nature Reviews Cancer, 15, 201–215.
6. + T cells that have been transduced to express a WT1-specific T cell receptor can persist and provide anti-leukemic activity in AML patients post-transplant. Blood, 124, 3939.
7. Becker, J.C., Andersen, M.H., Hofmeister-Muller, V., Wobser, M., Frey, L., Sandig, C., Walter, S., Singh-Jasuja, H., Kampgen, E., Opitz, A., Zapatka, M., Brocker, E.B., Thor Straten, P., Schrama, D. & Ugurel, S. (2012) Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunology, Immunotherapy, 61, 2091–2103.
8. Bellantuono, I., Gao, L., Parry, S., Marley, S., Dazzi, F., Apperley, J., Goldman, J.M. & Stauss, H.J. (2002) Two distinct HLA-A0201-presented epitopes of the wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood, 100, 3835–3837.
9. Bollard, C.M. & Heslop, H.E. (2016) T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood, 127, 3331–3340.
10. Bollard, C.M., Gottschalk, S., Torrano, V., Diouf, O., Ku, S., Hazrat, Y., Carrum, G., Ramos, C., Fayad, L., Shpall, E.J., Pro, B., Liu, H., Wu, M.F., Lee, D., Sheehan, A.M., Zu, Y., Gee, A.P., Brenner, M.K., Heslop, H.E. & Rooney, C.M. (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting epstein-barr virus latent membrane proteins. Journal of Clinical Oncology, 32, 798–808.
11. Brentjens, R.J., Riviere, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., Olszewska, M., Bernal, Y., Pegram, H., Przybylowski, M., Hollyman, D., Usachenko, Y., Pirraglia, D., Hosey, J., Santos, E., Halton, E., Maslak, P., Scheinberg, D., Jurcic, J., Heaney, M., Heller, G., Frattini, M. & Sadelain, M. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 118, 4817–4828.
12. Cameron, B.J., Gerry, A.B., Dukes, J., Harper, J.V., Kannan, V., Bianchi, F.C., Grand, F., Brewer, J.E., Gupta, M., Plesa, G., Bossi, G., Vuidepot, A., Powlesland, A.S., Legg, A., Adams, K.J., Bennett, A.D., Pumphrey, N.J., Williams, D.D., Binder-Scholl, G., Kulikovskaya, I., Levine, B.L., Riley, J.L., Varela-Rohena, A., Stadtmauer, E.A., Rapoport, A.P., Linette, G.P., June, C.H., Hassan, N.J., Kalos, M. & Jakobsen, B.K. (2013) Identification of a titin-derived HLA-A1-Presented peptide as a cross-reactive target for engineered mage A3-directed T cells. Science Translational Medicine, 5, 197ra103.
13. Carpenter, R.O., Evbuomwan, M.O., Pittaluga, S., Rose, J.J., Raffeld, M., Yang, S., Gress, R.E., Hakim, F.T. & Kochenderfer, J.N. (2013) B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clinical Cancer Research, 19, 2048–2060.
14. Casucci, M., Nicolis Di Robilant, B., Falcone, L., Camisa, B., Norelli, M., Genovese, P., Gentner, B., Gullotta, F., Ponzoni, M., Bernardi, M., Marcatti, M., Saudemont, A., Bordignon, C., Savoldo, B., Ciceri, F., Naldini, L., Dotti, G., Bonini, C. & Bondanza, A. (2013) CD44V6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood, 122, 3461–3472.
15. + T cells can mediate antileukemic activity and persist in post-transplant patients. Science Translational Medicine, 5, 174ra127.
16. Cheever, M.A., Allison, J.P., Ferris, A.S., Finn, O.J., Hastings, B.M., Hecht, T.T., Mellman, I., Prindiville, S.A., Viner, J.L., Weiner, L.M. & Matrisian, L.M. (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clinical Cancer Research, 15, 5323–5337.
17. Ciceri, F., Bonini, C., Stanghellini, M.T., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., Pescarollo, A., Servida, P., Magnani, Z., Perna, S.K., Valtolina, V., Crippa, F., Callegaro, L., Spoldi, E., Crocchiolo, R., Fleischhauer, K., Ponzoni, M., Vago, L., Rossini, S., Santoro, A., Todisco, E., Apperley, J., Olavarria, E., Slavin, S., Weissinger, E.M., Ganser, A., Stadler, M., Yannaki, E., Fassas, A., Anagnostopoulos, A., Bregni, M., Stampino, C.G., Bruzzi, P. & Bordignon, C. (2009) Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (The TK007 trial): a non-randomised phase I-II study. The Lancet Oncology, 10, 489–500.
18. Cruz, C.R., Micklethwaite, K.P., Savoldo, B., Ramos, C.A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A.J., Ito, S., Shpall, E.J., Krance, R.A., Kamble, R.T., Carrum, G., Hosing, C.M., Gee, A.P., Mei, Z., Grilley, B.J., Heslop, H.E., Rooney, C.M., Brenner, M.K., Bollard, C.M. & Dotti, G. (2013) Infusion of donor-derived CD19-redirected virus-specific T Cells For B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood, 122, 2965–2973.
19. Curran, K.J., Seinstra, B.A., Nikhamin, Y., Yeh, R., Usachenko, Y., Van Leeuwen, D.G., Purdon, T., Pegram, H.J. & Brentjens, R.J. (2015) Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Molecular Therapy, 23, 769–778.
20. Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., Qu, J., Wasielewska, T., He, Q., Fink, M., Shinglot, H., Youssif, M., Satter, M., Wang, Y., Hosey, J., Quintanilla, H., Halton, E., Bernal, Y., Bouhassira, D.C., Arcila, M.E., Gonen, M., Roboz, G.J., Maslak, P., Douer, D., Frattini, M.G., Giralt, S., Sadelain, M. & Brentjens, R. (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Translational Medicine., 6, 224ra225.
21. Di Stasi, A., Tey, S.K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A.G., Grilley, B., Liu, H., Cruz, C.R., Savoldo, B., Gee, A.P., Schindler, J., Krance, R.A., Heslop, H.E., Spencer, D.M., Rooney, C.M. & Brenner, M.K. (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. New England Journal of Medicine, 365, 1673–1683.
22. Doubrovina, E., Oflaz-Sozmen, B., Prockop, S.E., Kernan, N.A., Abramson, S., Teruya-Feldstein, J., Hedvat, C., Chou, J.F., Heller, G., Barker, J.N., Boulad, F., Castro-Malaspina, H., George, D., Jakubowski, A., Koehne, G., Papadopoulos, E.B., Scaradavou, A., Small, T.N., Khalaf, R., Young, J.W. & O'reilly, R.J. (2012) Adoptive immunotherapy with unselected or ebv-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood, 119, 2644–2656.
23. Dutour, A., Marin, V., Pizzitola, I., Valsesia-Wittmann, S., Lee, D., Yvon, E., Finney, H., Lawson, A., Brenner, M., Biondi, A., Biagi, E. & Rousseau, R. (2012) In vitro and in vivo antitumor effect of Anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Advances in Hematology, 2012, 683065.
24. Eshhar, Z., Waks, T., Gross, G. & Schindler, D.G. (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America, 90, 720–724.
25. Frigault, M.J., Lee, J., Basil, M.C., Carpenito, C., Motohashi, S., Scholler, J., Kawalekar, O.U., Guedan, S., Mcgettigan, S.E., Posey, A.D. Jr, Ang, S., Cooper, L.J., Platt, J.M., Johnson, F.B., Paulos, C.M., Zhao, Y., Kalos, M., Milone, M.C. & June, C.H. (2015) Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunology Research, 3, 356–367.
26. Garde, D. & Keshavan, M. (2016) Juno halts its immunotherapy trial for cancer after three patient deaths. Available at https://www.statnews.com/2016/07/07/juno-cancer-immunotherapy-deaths/
27. Garfall, A.L., Maus, M.V., Hwang, W.T., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Zheng, Z., Vogl, D.T., Cohen, A.D., Weiss, B.M., Dengel, K., Kerr, N.D., Bagg, A., Levine, B.L., June, C.H. & Stadtmauer, E.A. (2015) Chimeric antigen receptor T cells against CD19 for multiple myeloma. New England Journal of Medicine, 373, 1040–1047.
28. Gerdemann, U., Katari, U., Christin, A.S., Cruz, C.R., Tripic, T., Rousseau, A., Gottschalk, S.M., Savoldo, B., Vera, J.F., Heslop, H.E., Brenner, M.K., Bollard, C.M., Rooney, C.M. & Leen, A.M. (2011) Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Molecular Therapy, 19, 2258–2268.
29. Gill, S., Tasian, S.K., Ruella, M., Shestova, O., Li, Y., Porter, D.L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S.A., June, C.H. & Kalos, M. (2014) Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood, 123, 2343–2354.
30. Gros, A., Parkhurst, M.R., Tran, E., Pasetto, A., Robbins, P.F., Ilyas, S., Prickett, T.D., Gartner, J.J., Crystal, J.S., Roberts, I.M., Trebska-Mcgowan, K., Wunderlich, J.R., Yang, J.C. & Rosenberg, S.A. (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nature Medicine, 22, 433–438.
31. Haque, T., Wilkie, G.M., Jones, M.M., Higgins, C.D., Urquhart, G., Wingate, P., Burns, D., Mcaulay, K., Turner, M., Bellamy, C., Amlot, P.L., Kelly, D., Macgilchrist, A., Gandhi, M.K., Swerdlow, A.J. & Crawford, D.H. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood, 110, 1123–1131.
32. Haso, W., Lee, D.W., Shah, N.N., Stetler-Stevenson, M., Yuan, C.M., Pastan, I.H., Dimitrov, D.S., Morgan, R.A., Fitzgerald, D.J., Barrett, D.M., Wayne, A.S., Mackall, C.L. & Orentas, R.J. (2013) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, 121, 1165–1174.
33. Heslop, H.E., Slobod, K.S., Pule, M.A., Hale, G.A., Rousseau, A., Smith, C.A., Bollard, C.M., Liu, H., Wu, M.F., Rochester, R.J., Amrolia, P.J., Hurwitz, J.L., Brenner, M.K. & Rooney, C.M. (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 115, 925–935.
34. Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., Kolb, H.-J., Rimm, A.A., Ringden, O., Rozman, C., Speck, B., Truitt, R.L., Zwaan, F.E. & Bortin, M.M. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555–562.
35. Hudecek, M., Sommermeyer, D., Kosasih, P.L., Silva-Benedict, A., Liu, L., Rader, C., Jensen, M.C. & Riddell, S.R. (2015) The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunology Research, 3, 125–135.
36. Icheva, V., Kayser, S., Wolff, D., Tuve, S., Kyzirakos, C., Bethge, W., Greil, J., Albert, M.H., Schwinger, W., Nathrath, M., Schumm, M., Stevanovic, S., Handgretinger, R., Lang, P. & Feuchtinger, T. (2013) Adoptive transfer of epstein-barr virus (EBV) Nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. Journal of Clinical Oncology, 31, 39–48.
37. Jensen, M.C., Popplewell, L., Cooper, L.J., Digiusto, D., Kalos, M., Ostberg, J.R. & Forman, S.J. (2010) Anti-transgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor re-directed T cells in humans. Biology of Blood and Marrow Transplantation, 16, 1245–1256.
38. June, C.H., Riddell, S.R. & Schumacher, T.N. (2015) Adoptive cellular therapy: a race to the finish line. Science Translational Medicine, 7, 280 ps287.
39. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A. & June, C.H. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine, 3, 95ra73.
40. Kawalekar, O.U., O'connor, R.S., Fraietta, J.A., Guo, L., Mcgettigan, S.E., Posey, A.D. Jr, Patel, P.R., Guedan, S., Scholler, J., Keith, B., Snyder, N., Blair, I., Milone, M.C. & June, C.H. (2016) Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity, 44, 380–390.
41. Kebriaei, P., Singh, H., Huls, M.H., Figliola, M.J., Bassett, R., Olivares, S., Jena, B., Dawson, M.J., Kumaresan, P.R., Su, S., Maiti, S., Dai, J., Moriarity, B., Forget, M.A., Senyukov, V., Orozco, A., Liu, T., Mccarty, J., Jackson, R.N., Moyes, J.S., Rondon, G., Qazilbash, M., Ciurea, S., Alousi, A., Nieto, Y., Rezvani, K., Marin, D., Popat, U., Hosing, C., Shpall, E.J., Kantarjian, H., Keating, M., Wierda, W., Do, K.A., Largaespada, D.A., Lee, D.A., Hackett, P.B., Champlin, R.E. & Cooper, L.J. (2016) Phase I trials using sleeping beauty to generate CD19-specific CAR T cells. The Journal of Clinical Investigation, 126, 3363–3376.
42. Kenderian, S.S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V., Morrissette, J.J., Scholler, J., Song, D., Porter, D.L., Carroll, M., June, C.H. & Gill, S. (2015) CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia, 29, 1637–1647.
43. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., Maric, I., Raffeld, M., Nathan, D.A., Lanier, B.J., Morgan, R.A. & Rosenberg, S.A. (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood, 116, 4099–4102.
44. Kochenderfer, J.N., Dudley, M.E., Kassim, S.H., Somerville, R.P., Carpenter, R.O., Stetler-Stevenson, M., Yang, J.C., Phan, G.Q., Hughes, M.S., Sherry, R.M., Raffeld, M., Feldman, S., Lu, L., Li, Y.F., Ngo, L.T., Goy, A., Feldman, T., Spaner, D.E., Wang, M.L., Chen, C.C., Kranick, S.M., Nath, A., Nathan, D.A., Morton, K.E., Toomey, M.A. & Rosenberg, S.A. (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology, 33, 540–549.
45. Kohn, D.B., Porteus, M.H. & Scharenberg, A.M. (2016) Ethical and regulatory aspects of genome editing. Blood, 127, 2553–2560.
46. Kolb, H.J. (2008) Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood, 112, 4371–4383.
47. Kolb, H.J., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M. & Wilmanns, W. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462–2465.
48. Lee, D.W., Gardner, R., Porter, D.L., Louis, C.U., Ahmed, N., Jensen, M., Grupp, S.A. & Mackall, C.L. (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124, 188–195.
49. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., Steinberg, S.M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S.A., Wayne, A.S. & Mackall, C.L. (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet, 385, 517–528.
50. Leen, A.M., Bollard, C.M., Mendizabal, A.M., Shpall, E.J., Szabolcs, P., Antin, J.H., Kapoor, N., Pai, S.Y., Rowley, S.D., Kebriaei, P., Dey, B.R., Grilley, B.J., Gee, A.P., Brenner, M.K., Rooney, C.M. & Heslop, H.E. (2013) Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood, 121, 5113–5123.
51. Leen, A.M., Tzannou, I., Bilgi, M., Liu, H., Vera, J.F., Gerdemann, U., Kamble, R., Ramos, C.A., Grilley, B., Gee, A., Bollard, C.M., Brenner, M.K., Heslop, H.E., Rooney, C.M. & Carrum, G. (2015) Immunotherapy for lymphoma using T cells targeting multiple tumor associated antigens. Blood, 126, 1926.
52. Linette, G.P., Stadtmauer, E.A., Maus, M.V., Rapoport, A.P., Levine, B.L., Emery, L., Litzky, L., Bagg, A., Carreno, B.M., Cimino, P.J., Binder-Scholl, G.K., Smethurst, D.P., Gerry, A.B., Pumphrey, N.J., Bennett, A.D., Brewer, J.E., Dukes, J., Harper, J., Tayton-Martin, H.K., Jakobsen, B.K., Hassan, N.J., Kalos, M. & June, C.H. (2013) Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood, 122, 863–871.
53. Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., Smith, J.P., Walker, A.J., Kohler, M.E., Venkateshwara, V.R., Kaplan, R.N., Patterson, G.H., Fry, T.J., Orentas, R.J. & Mackall, C.L. (2015) 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nature Medicine, 21, 581–590.
54. Lynn, R.C., Feng, Y., Schutsky, K., Poussin, M., Kalota, A., Dimitrov, D.S. & Powell, D.J. Jr (2016) High-affinity frbeta-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity. Leukemia, 30, 1355–1364.
55. Mamonkin, M., Rouce, R.H., Tashiro, H. & Brenner, M.K. (2015) A T-cell-directed chimeric antigen receptor for the selective treatment of T-Cell malignancies. Blood, 126, 983–992.
56. Mardiros, A., Dos Santos, C., Mcdonald, T., Brown, C.E., Wang, X., Budde, L.E., Hoffman, L., Aguilar, B., Chang, W.C., Bretzlaff, W., Chang, B., Jonnalagadda, M., Starr, R., Ostberg, J.R., Jensen, M.C., Bhatia, R. & Forman, S.J. (2013) T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, 122, 3138–3148.
57. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Rheingold, S.R., Shen, A., Teachey, D.T., Levine, B.L., June, C.H., Porter, D.L. & Grupp, S.A. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine, 371, 1507–1517.
58. Molldrem, J.J., Lee, P.P., Wang, C., Felio, K., Kantarjian, H.M., Champlin, R.E. & Davis, M.M. (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine, 6, 1018–1023.
59. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M. & Rosenberg, S.A. (2010) Case report of a serious adverse event following the administration of T Cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy, 18, 843–851.
60. Morris, E.C. & Stauss, H.J. (2016) Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood, 127, 3305–3311.
61. Ngo, M.C., Ando, J., Leen, A.M., Ennamuri, S., Lapteva, N., Vera, J.F., Min-Venditti, A., Mims, M.P., Heslop, H.E., Bollard, C.M., Gottschalk, S. & Rooney, C.M. (2014) Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. Journal of Immunotherapy, 37, 193–203.
62. Noonan, K.A., Huff, C.A., Davis, J., Lemas, M.V., Fiorino, S., Bitzan, J., Ferguson, A., Emerling, A., Luznik, L., Matsui, W., Powell, J., Fuchs, E., Rosner, G.L., Epstein, C., Rudraraju, L., Ambinder, R.F., Jones, R.J., Pardoll, D. & Borrello, I. (2015) Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Science Translational Medicine, 7, 288ra278.
63. O'reilly, R.J., Dao, T., Koehne, G., Scheinberg, D. & Doubrovina, E. (2010) Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Semin.Immunol., 22, 162–172.
64. Papadopoulos, E.B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M.H., Castro-Malaspina, H., Childs, B.H., Gillio, A.P., Small, T.N., Young, J.W., Kernan, N.A. & O'reilly, R.J. (1994) Infusions of donor leukocytes to treat epstein-barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N.Engl.J.Med., 330, 1185–1191.
65. Papadopoulou, A., Gerdemann, U., Katari, U.L., Tzannou, I., Liu, H., Martinez, C., Leung, K., Carrum, G., Gee, A.P., Vera, J.F., Krance, R.A., Brenner, M.K., Rooney, C.M., Heslop, H.E. & Leen, A.M. (2014a) Activity of broad-spectrum T cells as treatment for ADV, EBV, CMV, BKV, and HHV6 infections after HSCT. Science Translational Medicine, 6, 242ra283.
66. Papadopoulou, A., Krance, R.A., Allen, C.E., Lee, D., Rooney, C.M., Brenner, M.K., Leen, A.M. & Heslop, H.E. (2014b) Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Molecular Therapy, 22, 1134–1138.
67. Park, J.H., Geyer, M.B. & Brentjens, R.J. (2016) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood, 127, 3312–3320.
68. Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., Lebuhotel, C., Eyquem, J., Cheung, G.W., Duclert, A., Gouble, A., Arnould, S., Peggs, K., Pule, M., Scharenberg, A.M. & Smith, J. (2015) Multiplex genome-edited T-cell manufacturing platform for ‘Off-The-Shelf’ adoptive T-cell immunotherapies. Cancer Research, 75, 3853–3864.
69. Porter, D.L., Hwang, W.T., Frey, N.V., Lacey, S.F., Shaw, P.A., Loren, A.W., Bagg, A., Marcucci, K.T., Shen, A., Gonzalez, V., Ambrose, D., Grupp, S.A., Chew, A., Zheng, Z., Milone, M.C., Levine, B.L., Melenhorst, J.J. & June, C.H. (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 7, 303ra139.
70. Qasim, W., Amrolia, P.J., Samarasinghe, S., Ghorashian, S., Zhan, H., Stafford, S., Butler, K., Ahsan, G., Gilmour, K., Adams, S., Pinner, D., Chiesa, R., Chatters, S., Swift, S., Goulden, N., Peggs, K., Thrasher, A.J., Veys, P. & Pule, M. (2015) First clinical application of talen engineered universal CAR19 T cells in B-ALL. Blood, 126, 2046.
71. Quintarelli, C., Dotti, G., Hasan, S.T., De, A.B., Hoyos, V., Errichiello, S., Mims, M., Luciano, L., Shafer, J., Leen, A.M., Heslop, H.E., Rooney, C.M., Pane, F., Brenner, M.K. & Savoldo, B. (2011) High-avidity cytotoxic T lymphocytes specific for a new prame-derived peptide can target leukemic and leukemic-precursor cells. Blood, 117, 3353–3362.
72. + hodgkin and non-hodgkin lymphomas. Blood, 126, 185.
73. Ramos, C.A., Savoldo, B., Torrano, V., Ballard, B., Zhang, H., Dakhova, O., Liu, E., Carrum, G., Kamble, R.T., Gee, A.P., Mei, Z., Wu, M.F., Liu, H., Grilley, B., Rooney, C.M., Brenner, M.K., Heslop, H.E. & Dotti, G. (2016) Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains. The Journal of Clinical Investigation, 126, 2588–2596.
74. Rapoport, A.P., Aqui, N.A., Stadtmauer, E.A., Vogl, D.T., Fang, H.B., Cai, L., Janofsky, S., Chew, A., Storek, J., Akpek, G., Badros, A., Yanovich, S., Tan, M.T., Veloso, E., Pasetti, M.F., Cross, A., Philip, S., Murphy, H., Bhagat, R., Zheng, Z., Milliron, T., Cotte, J., Cannon, A., Levine, B.L., Vonderheide, R.H. & June, C.H. (2011) Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of Htert and survivin after Asct for myeloma. Blood, 117, 788–797.
75. Rapoport, A.P., Stadtmauer, E.A., Binder-Scholl, G.K., Goloubeva, O., Vogl, D.T., Lacey, S.F., Badros, A.Z., Garfall, A., Weiss, B., Finklestein, J., Kulikovskaya, I., Sinha, S.K., Kronsberg, S., Gupta, M., Bond, S., Melchiori, L., Brewer, J.E., Bennett, A.D., Gerry, A.B., Pumphrey, N.J., Williams, D., Tayton-Martin, H.K., Ribeiro, L., Holdich, T., Yanovich, S., Hardy, N., Yared, J., Kerr, N., Philip, S., Westphal, S., Siegel, D.L., Levine, B.L., Jakobsen, B.K., Kalos, M. & June, C.H. (2015) Ny-Eso-1-specific Tcr-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine, 21, 914–921.
76. Ritchie, D.S., Neeson, P.J., Khot, A., Peinert, S., Tai, T., Tainton, K., Chen, K., Shin, M., Wall, D.M., Honemann, D., Gambell, P., Westerman, D.A., Haurat, J., Westwood, J.A., Scott, A.M., Kravets, L., Dickinson, M., Trapani, J.A., Smyth, M.J., Darcy, P.K., Kershaw, M.H. & Prince, H.M. (2013) Persistence and efficacy of second generation CAR T cell against the ley antigen in acute myeloid leukemia. Molecular Therapy, 21, 2122–2129.
77. Robbins, P.F., Morgan, R.A., Feldman, S.A., Yang, J.C., Sherry, R.M., Dudley, M.E., Wunderlich, J.R., Nahvi, A.V., Helman, L.J., Mackall, C.L., Kammula, U.S., Hughes, M.S., Restifo, N.P., Raffeld, M., Lee, C.C., Levy, C.L., Li, Y.F., El-Gamil, M., Schwarz, S.L., Laurencot, C. & Rosenberg, S.A. (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with Ny-Eso-1. Journal of Clinical Oncology, 29, 917–924.
78. Rooney, C.M., Smith, C.A., Ng, C.Y., Loftin, S., Li, C., Krance, R.A., Brenner, M.K. & Heslop, H.E. (1995) Use of gene-modified virus-specific T lymphocytes to control epstein-barr-virus-related lymphoproliferation. Lancet, 345, 9–13.
79. Rooney, C.M., Leen, A.M., Vera, J.F. & Heslop, H.E. (2014) T lymphocytes targeting native receptors. Immunological Reviews, 257, 39–55.
80. Rosenberg, S.A., Spiess, P. & Lafreniere, R. (1986) A new approach to the adoptive immunotherapy of cancer with tumor- infiltrating lymphocytes. Science, 233, 1318–1321.
81. Rouce, R.H. & Heslop, H.E. (2016) Forecasting cytokine storms with new predictive biomarkers. Cancer Discovery, 6, 579–580.
82. Ruella, M., Kenderian, S.S., Shestova, O., Fraietta, J.A., Qayyum, S., Zhang, Q., Maus, M.V., Liu, X., Nunez-Cruz, S., Klichinsky, M., Kawalekar, O.U., Milone, M., Lacey, S.F., Mato, A., Schuster, S.J., Kalos, M., June, C.H., Gill, S. & Wasik, M.A. (2016) The addition of the BTK inhibitor ibrutinib to Anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clinical Cancer Research, 22, 2684–2696.
83. Sadelain, M. (2015) CAR therapy: the CD19 paradigm. The Journal of Clinical Investigation, 125, 3392–3400.
84. Sadelain, M. (2016) Chimeric antigen receptors: driving immunology towards synthetic biology. Current Opinion in Immunology, 41, 68–76.
85. Savoldo, B., Ramos, C.A., Liu, E., Mims, M.P., Keating, M.J., Carrum, G., Kamble, R.T., Bollard, C.M., Gee, A.P., Mei, Z., Liu, H., Grilley, B., Rooney, C.M., Heslop, H.E., Brenner, M.K. & Dotti, G. (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. The Journal of Clinical Investigation, 121, 1822–1826.
86. Schumacher, T.N. & Schreiber, R.D. (2015) Neoantigens in cancer immunotherapy. Science, 348, 69–74.
87. + lymphomas. Blood, 126, 183.
88. Singh, N., Perazzelli, J., Grupp, S.A. & Barrett, D.M. (2016) Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Science Translational Medicine, 8, 320ra323.
89. Sotillo, E., Barrett, D.M., Black, K.L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M.R., Martinez, N.M., Harrington, C.T., Chung, E.Y., Perazzelli, J., Hofmann, T.J., Maude, S.L., Raman, P., Barrera, A., Gill, S., Lacey, S.F., Melenhorst, J.J., Allman, D., Jacoby, E., Fry, T., Mackall, C., Barash, Y., Lynch, K.W., Maris, J.M., Grupp, S.A. & Thomas-Tikhonenko, A. (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discovery, 5, 1282–1295.
90. Taylor, G.S., Long, H.M., Brooks, J.M., Rickinson, A.B. & Hislop, A.D. (2015) The immunology of Epstein-Barr Virus-induced disease. Annual Review of Immunology, 33, 787–821.
91. Teachey, D.T., Lacey, S.F., Shaw, P.A., Melenhorst, J.J., Maude, S.L., Frey, N., Pequignot, E., Gonzalez, V.E., Chen, F., Finklestein, J., Barrett, D.M., Weiss, S.L., Fitzgerald, J.C., Berg, R.A., Aplenc, R., Callahan, C., Rheingold, S.R., Zheng, Z., Rose-John, S., White, J.C., Nazimuddin, F., Wertheim, G., Levine, B.L., June, C.H., Porter, D.L. & Grupp, S.A. (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discovery, 6, 664–679.
92. Till, B.G., Jensen, M.C., Wang, J., Qian, X., Gopal, A.K., Maloney, D.G., Lindgren, C.G., Lin, Y., Pagel, J.M., Budde, L.E., Raubitschek, A., Forman, S.J., Greenberg, P.D., Riddell, S.R. & Press, O.W. (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood, 119, 3940–3950.
93. Torikai, H. & Cooper, L.J. (2016) Translational implications for off-the-shelf immune cells expressing chimeric antigen receptors. Molecular Therapy, 24, 1178–1186.
94. + CD19-specific chimeric antigen receptor-modified T cells. Science Translational Medicine, 8, 355ra116.
95. + composition in adult B cell ALL patients. The Journal of Clinical Investigation, 126, 2123–2138.
96. Vickers, M.A., Wilkie, G.M., Robinson, N., Rivera, N., Haque, T., Crawford, D.H., Barry, J., Fraser, N., Turner, D.M., Robertson, V., Dyer, P., Flanagan, P., Newlands, H.R., Campbell, J. & Turner, M.L. (2014) Establishment and operation of a good manufacturing practice-compliant allogeneic Epstein-Barr Virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. British Journal of Haematology, 167, 402–410.
97. Vonderheide, R.H. & June, C.H. (2014) Engineering T cells for cancer: our synthetic future. Immunological Reviews, 257, 7–13.
98. Wang, Q.S., Wang, Y., Lv, H.Y., Han, Q.W., Fan, H., Guo, B., Wang, L.L. & Han, W.D. (2015) Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Molecular Therapy, 23, 184–191.
99. Warren, E.H., Fujii, N., Akatsuka, Y., Chaney, C.N., Mito, J.K., Loeb, K.R., Gooley, T.A., Brown, M.L., Koo, K.K., Rosinski, K.V., Ogawa, S., Matsubara, A., Appelbaum, F.R. & Riddell, S.R. (2010) Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood, 115, 3869–3878.
100. Weber, G., Caruana, I., Rouce, R.H., Barrett, A.J., Gerdemann, U., Leen, A.M., Rabin, K.R. & Bollard, C.M. (2013) Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia-implications for immunotherapy. Clinical Cancer Research, 19, 5079–5091.
101. Zhou, X., Dotti, G., Krance, R.A., Martinez, C.A., Naik, S., Kamble, R.T., Durett, A.G., Dakhova, O., Savoldo, B., Di Stasi, A., Spencer, D.M., Lin, Y.F., Liu, H., Grilley, B.J., Gee, A.P., Rooney, C.M., Heslop, H.E. & Brenner, M.K. (2015) Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood, 125, 4103–4113.